Related Experiment Video
Updated: Mar 24, 2026
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
Olaparib for the treatment of ovarian cancer
1Department of Internal Medicine, Division of Hematology and Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA. ethan.bornstein@ucdenver.edu.
Abstract:
Olaparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, is the first FDA-approved drug in its class for patients with ovarian cancer, specifically in a subset of patients with BRCA mutations and prior chemotherapy treatments. PARP inhibitors have had other implications in different solid tumor types including breast, gastric and pancreatic malignancies. In light of the recent FDA approval of olaparib for the treatment of ovarian cancer, this article aims to outline the mechanisms and implications of the drug. With a favorable adverse event profile and improved outcomes, including progression-free survival, olaparib has demonstrated augmentation to therapeutic options in the treatment of ovarian cancer.
Insights
Olaparib is a new oral PARP inhibitor for BRCA-mutated ovarian cancer. This drug offers improved progression-free survival and a favorable safety profile, expanding treatment options.
Area of Science:
- Oncology
- Pharmacology
Background:
- Olaparib is the first FDA-approved poly(ADP-ribose) polymerase (PARP) inhibitor for ovarian cancer.
- It is indicated for a subset of patients with BRCA mutations and prior chemotherapy.
- PARP inhibitors show promise in other solid tumors like breast, gastric, and pancreatic cancers.
Purpose of the Study:
- To outline the mechanisms and implications of olaparib.
- To discuss its role in ovarian cancer treatment following FDA approval.
Main Methods:
- Review of clinical data and FDA approval information for olaparib.
- Analysis of olaparib's mechanism of action as a PARP inhibitor.
Main Results:
- Olaparib demonstrated improved progression-free survival in ovarian cancer patients.
- The drug exhibits a favorable adverse event profile.
- Olaparib offers augmented therapeutic options for ovarian cancer.
Conclusions:
- Olaparib represents a significant advancement in ovarian cancer therapy.
- Its efficacy and safety profile support its role in treating specific patient populations.
- Further implications for other solid tumors are being explored.
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies